GLUE: Bowen Matthew sold shares
- 13 shares sold on 10/05/2026
- Price: $10.56
- 25,891 shares owned after transaction
Matthew Bowen
GLUE
Monte Rosa Therapeutics, Inc. SEC filings
Every EDGAR filing for Monte Rosa Therapeutics, Inc. (GLUE), newest first, with AI summaries and stories.
- Ticker
- GLUE
- CIK
- 1826457
- Sector
- Biotech and pharma
- Latest filing
- Oct 6
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 16)
Insider activity
No open-market insider buys in the last 30 days.
Also: 1 open-market sale ($137).
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE ROUTINE8-KMonte Rosa Therapeutics, Inc.GLUELIVE ROUTINE8-KMonte Rosa Therapeutics, Inc.GLUELIVE ROUTINESCHEDULE 13G/AMonte Rosa Therapeutics, Inc.GLUELIVE 2 13G filings
Ownership stake disclosure by MONTANOVA CAPITAL, LLC (amended)
Show all 2
- SCHEDULE 13G/AOwnership stake disclosure (amended)
- SCHEDULE 13GOwnership stake disclosure
MONTANOVA CAPITAL, LLC, filed by
NOTABLE10-QMonte Rosa Therapeutics, Inc.GLUELIVE ROUTINE8-KMonte Rosa Therapeutics, Inc.GLUELIVE ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Markus Warmuth, insider filing for GLUE
Markus Warmuth, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, insider filing for GLUE
Jennifer Champoux, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Markus Warmuth, planned sale of GLUE shares
Markus Warmuth, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, planned sale of GLUE shares
Jennifer Champoux, reporting
ROUTINESCHEDULE 13G/AMonte Rosa Therapeutics, Inc.GLUELIVE Ownership stake disclosure by PRICE T ROWE ASSOCIATES INC /MD/ (amended)
PRICE T ROWE ASSOCIATES INC /MD/, filed by
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Sharon Townson, insider filing for GLUE
Sharon Townson, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Ali Behbahani, insider filing for GLUE
Ali Behbahani, reporting
NOTABLESCHEDULE 13D/AMonte Rosa Therapeutics, Inc.GLUELIVE Ownership stake disclosure by New Enterprise Associates 17, L.P. (amended)
New Enterprise Associates 17, L.P., filed by
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Filip Janku, insider filing for GLUE
Filip Janku, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Filip Janku, planned sale of GLUE shares
Filip Janku, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE 2 insider filings
Filip Janku, insider filing for GLUE
Show all 2
- 4Insider filing for GLUE
- 4Insider filing for GLUE
Filip Janku, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE 2 Form 144 notices
Filip Janku, planned sale of GLUE shares
Show all 2
- 144Planned insider sale of GLUE shares
- 144Planned insider sale of GLUE shares
Filip Janku, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE 3 insider filings
Jennifer Champoux, insider filing for GLUE
Show all 3
- 4Insider filing for GLUE
- 4Insider filing for GLUE
- 4Insider filing for GLUE
Jennifer Champoux, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Filip Janku, planned sale of GLUE shares
Filip Janku, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE 3 Form 144 notices
Filip Janku, planned sale of GLUE shares
Show all 3
- 144Planned insider sale of GLUE shares
- 144Planned insider sale of GLUE shares
- 144Planned insider sale of GLUE shares
Filip Janku, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE 2 insider filings
Sharon Townson, insider filing for GLUE
Show all 2
- 4Insider filing for GLUE
- 4Insider filing for GLUE
Sharon Townson, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, planned sale of GLUE shares
Jennifer Champoux, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Ali Behbahani, insider filing for GLUE
Ali Behbahani, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE 6 insider filings
Anthony M. Manning, insider filing for GLUE
Show all 6
- 4Insider filing for GLUE
- 4Insider filing for GLUE
- 4Insider filing for GLUE
- 4Insider filing for GLUE
- 4Insider filing for GLUE
- 4Insider filing for GLUE
Anthony M. Manning, reporting
ROUTINE8-KMonte Rosa Therapeutics, Inc.GLUELIVE ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Markus Warmuth, insider filing for GLUE
Markus Warmuth, reporting
ROUTINE144/AMonte Rosa Therapeutics, Inc.GLUELIVE Markus Warmuth, planned sale of GLUE shares (amended)
Markus Warmuth, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Markus Warmuth, planned sale of GLUE shares
Markus Warmuth, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Sharon Townson, insider filing for GLUE
Sharon Townson, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Sharon Townson, planned sale of GLUE shares
Sharon Townson, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, insider filing for GLUE
Jennifer Champoux, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, planned sale of GLUE shares
Jennifer Champoux, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, insider filing for GLUE
Jennifer Champoux, reporting
ROUTINE4Monte Rosa Therapeutics, Inc.GLUELIVE Anthony M. Manning, insider filing for GLUE
Anthony M. Manning, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Jennifer Champoux, planned sale of GLUE shares
Jennifer Champoux, reporting
ROUTINE144Monte Rosa Therapeutics, Inc.GLUELIVE Anthony M. Manning, planned sale of GLUE shares
Anthony M. Manning, reporting